Romidepsin: all 73 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology AgentsRecruitingNCT06963346Phase 1
• Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell MalignanciesCompletedNCT04447027Phase 1Results posted
• Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell LymphomaCompletedNCT03770000Phase 1/2Results posted
• Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)TerminatedNCT03547700Phase 1/2Results posted
• Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell LymphomaCompletedNCT03534180Phase 2Results posted
• Study of Pembrolizumab (MK-3475) in Combination With RomidepsinActive, not recruitingNCT03278782Phase 1/2Results posted
• Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell LymphomasCompletedNCT02341014Phase 1/2Results posted
• Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell LymphomaCompletedNCT02232516Phase 2Results posted
• Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host DiseaseTerminatedNCT02203578Not applicableResults posted
• Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid MalignanciesTerminatedNCT01998035Phase 1/2Results posted
• Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref MyelomaTerminatedNCT01979276Phase 1/2Results posted
• Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid MalignanciesTerminatedNCT01947140Phase 1/2Results posted
• Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast CancerTerminatedNCT01938833Phase 1/2Results posted
• Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral LoadCompletedNCT01933594Phase 1/2Results posted
• Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma PatientsCompletedNCT01822886Phase 2Results posted
• Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and MyelomaCompletedNCT01755975Phase 1/2Results posted
• Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell LymphomaTerminatedNCT01738594Phase 1Results posted
• A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)CompletedNCT01456039Phase 1/2Results posted
• A Rollover Study for Patients Who Participated in Other Romidepsin ProtocolsCompletedNCT01353664Phase 2Results posted
• Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced CancerCompletedNCT01324323Phase 1Results posted
• Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced CancerCompletedNCT01324310Phase 1Results posted
• Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT01302808Phase 1Results posted
• Trial of Romidepsin and Bortezomib for Multiple MyelomaTerminatedNCT00765102Phase 2Results posted
• A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell LymphomaCompletedNCT00426764Phase 2Results posted
• FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00383565Phase 2Results posted
• A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid TumorsCompletedNCT00379639Phase 1Results posted
• Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue SarcomaCompletedNCT00112463Phase 2Results posted
• A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)CompletedNCT00106431Phase 2Results posted
• Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive IodineCompletedNCT00098813Phase 2Results posted
• Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT00084682Phase 2Results posted
• Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell LymphomaCompletedNCT00007345Phase 2Results posted
• Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell LymphomasCompletedNCT04774068Phase 1
• Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell LymphomaWithdrawnNCT04639843Phase 1
• Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell LymphomaWithdrawnNCT04233697Phase 1
• Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for LymphomaStatus unknownNCT03161223Phase 1/2
• Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma PatientsCompletedNCT03141203Phase 1/2
• Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ARTCompletedNCT03041012Phase 2
• Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell LymphomasCompletedNCT02783625Phase 1
• Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCLWithdrawnNCT02757248Phase 1
• A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell LymphomaCompletedNCT02616965Phase 1
• Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected IndividualsCompletedNCT02616874Phase 1
• Romidepsin Maintenance After Allogeneic Stem Cell TransplantationCompletedNCT02512497Phase 1
• Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
• Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell LymphomasCompletedNCT02223208Phase 1/2
• Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive LymphomasCompletedNCT02181218Phase 1
• Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell LymphomaTerminatedNCT02061449Phase 1
• A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell LymphomaCompletedNCT01913119Early Phase 1
• Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell LymphomaCompletedNCT01902225Phase 1
• Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasCompletedNCT01897012Phase 1
• Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell LymphomaCompletedNCT01846390Phase 1
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT01590732Phase 1
• Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell LymphomaTerminatedNCT01445340Phase 1
• Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT00963274Phase 1
• A Research Study for Patients With Metastatic Renal Cell CarcinomaCompletedNCT00106613Phase 2
• A Research Study for Patients With Prostate CancerCompletedNCT00106418Phase 2
• Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228CompletedNCT00106301Phase 2
• FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction CancerTerminatedNCT00098527Phase 2
• FR901228 in Treating Patients With Metastatic Breast CancerCompletedNCT00098397Phase 2
• Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity CancerTerminatedNCT00091195Phase 2
• Romidepsin in Treating Patients With Relapsed Small Cell Lung CancerCompletedNCT00086827Phase 2
• Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsTerminatedNCT00084461Phase 2
• FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's LymphomaTerminatedNCT00079443Phase 2
• FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal CancerCompletedNCT00077337Phase 2
• FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00077194Phase 2
• FR901228 in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00066638Phase 2
• Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00062075Phase 2
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCompletedNCT00053963Phase 1
• Depsipeptide to Treat Thyroid and Other Advanced CancersCompletedNCT00048334Phase 1
• FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's LymphomaCompletedNCT00042822Phase 2
• FR901228 in Treating Patients With Hematologic CancerCompletedNCT00024180Phase 1
• FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung CancerCompletedNCT00020202Phase 2
• Depsipeptide in Treating Patients With Solid TumorsCompletedNCT00019318Phase 1

← Romidepsin overview